We are live on ! Find out more
INZY

Inozyme Pharma
INZY

Delisted

INZY was delisted on the 30th of June, 2025.

Back to rankings

77 hedge funds and large institutions have $205M invested in Inozyme Pharma in 2023 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 31 increasing their positions, 19 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

108% more call options, than puts

Call options by funds: $866K | Put options by funds: $416K

63% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 19

30% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 10

8% more capital invested

Capital invested by funds: $190M → $205M (+$14.4M)

4% more funds holding

Funds holding: 74 → 77 (+3)

1.37% more ownership

Funds ownership: 77.56% → 78.93% (+1.4%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
77
Holders Change
+3
Holders Change %
+4.05%
% of All Funds
1.22%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
13
Increased
31
Reduced
19
Closed
10
Calls
$866K
Puts
$416K
Net Calls
+$450K
Net Calls Change
+$587K

Top Buyers

Rank Fund Capital Flow
1
SC
Samlyn Capital
New York
+$16.5M
2
EAM
Eventide Asset Management
Massachusetts
+$15.9M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$8.73M
4
SB
Samsara BioCapital
California
+$7.95M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$6.55M

Top Sellers

Rank Fund Capital Flow
1
DTC
Deep Track Capital
Connecticut
-$9.16M
2
Millennium Management
Millennium Management
New York
-$4.47M
3
WP
Woodline Partners
California
-$1.61M
4
Walleye Capital
Walleye Capital
New York
-$1.05M
5
EI
EAM Investors
California
-$982K
Name Holding Trade Value Shares
Change 		Change in
Stake
Adage Capital Partners
1
Adage Capital Partners
Massachusetts
$23.3M +$6.55M +1,287,500 +30%
PBPIA
2
Pivotal bioVenture Partners Investment Advisor
California
$18.9M +$4.24M +833,333 +23%
SI
3
Sofinnova Investments
California
$18M +$3.18M +625,000 +17%
RSCM
4
Rock Springs Capital Management
Maryland
$15.5M +$1.29M +253,090 +7%
SC
5
Samlyn Capital
New York
$13.6M +$16.5M +3,245,208 New
EAM
6
Eventide Asset Management
Massachusetts
$13.1M +$15.9M +3,125,000 New
Fidelity Investments
7
Fidelity Investments
Massachusetts
$10.4M +$8.73M +1,716,398 +229%
NMC
8
NEA Management Company
Maryland
$10.2M – – –
Vanguard Group
9
Vanguard Group
Pennsylvania
$9.56M +$4.48M +880,175 +63%
BlackRock
10
BlackRock
New York
$9.41M +$1.53M +300,082 +15%
SB
11
Samsara BioCapital
California
$6.56M +$7.95M +1,562,500 New
AAA
12
Affinity Asset Advisors
New York
$5.8M +$3.19M +628,056 +84%
Millennium Management
13
Millennium Management
New York
$5.57M -$4.47M -879,287 -40%
OCA
14
Octagon Capital Advisors
New York
$5.46M +$6.36M +1,250,298 +2,516%
CA
15
CHI Advisors
New York
$5.33M +$382K +75,000 +6%
SFM
16
Sphera Funds Management
Israel
$5.19M +$524K +102,940 +9%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$3.46M +$1.04M +205,364 +33%
Point72 Asset Management
18
Point72 Asset Management
Connecticut
$2.94M +$3.56M +700,000 New
LCM
19
Laurion Capital Management
New York
$2.84M +$2.17M +426,961 +171%
State Street
20
State Street
Massachusetts
$2.64M +$343K +67,505 +12%
DMKJ
21
David M. Knott Jr
$1.91M +$1.19M +234,008 +106%
Northern Trust
22
Northern Trust
Illinois
$1.41M +$174K +34,264 +11%
MB
23
MPM BioImpact
Massachusetts
$1.37M – – –
SSA
24
Schonfeld Strategic Advisors
New York
$1.31M +$1.23M +242,080 +347%
Renaissance Technologies
25
Renaissance Technologies
New York
$1.24M +$287K +56,408 +24%
1
2 3 4

INZY Hedge Fund Activity: Q3 2023 in Review

77 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q3 2023, worth a combined $205M — up 7.6% from $190M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new INZY positions and 10 closed out — a net gain of 3 holders — while 31 added to existing stakes and 19 trimmed.

The largest buyer was Samlyn Capital, opening a new position worth an estimated $16.5M. The largest seller was Deep Track Capital, exiting entirely with an estimated $9.16M sold.

  • 77 institutional investors held Inozyme Pharma (INZY) as of Q3 2023, up from 74 in Q2 2023.
  • Funds reported $205M of Inozyme Pharma stock for Q3 2023, up 7.6% quarter-over-quarter.
  • 13 funds opened new Inozyme Pharma positions in Q3 2023 and 10 closed out, a net change of +3 holders.
  • The largest Inozyme Pharma buyer in Q3 2023 was Samlyn Capital, an estimated $16.5M added.
  • The largest Inozyme Pharma seller in Q3 2023 was Deep Track Capital, an estimated $9.16M sold.

Based on aggregated 13F filings for Q3 2023.